Back
Cara Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
CARA
Sponsored
Invest. Do Good. Get Rewarded. Just $0.26/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
20
CARA
Cara Therapeutics
Last Price:
0.31
Seasonality Move:
-4.11%
7 Day Trial
ALL ACCESS PASS
$
7
Say this - unlock as much as $1,250 every Friday
Click here for full details.Cara Therapeutics Price Quote
$0.31
Cara Therapeutics Key Stats
Sell
20
Cara Therapeutics (CARA)
is a Sell
Day range:
$0.30 - $0.32
52-week range:
$0.24 - $1.31
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.95
P/B ratio:
24.05%
Volume:
172.1K
Avg. volume:
684.3K
1-year change:
-69.31%
Market cap:
$17M
Revenue:
$21M
EPS:
$-1.75
How Much Does Cara Therapeutics Make?
-
How Much Are Cara Therapeutics's Sales Annually?
CARA Revenues are $21M -
How Much Profit Does Cara Therapeutics's Make A Year?
CARA net income is -$118.5M
Is Cara Therapeutics Growing As A Company?
-
What Is Cara Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.47% -
What Is Cara Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Cara Therapeutics Stock Price Performance
-
Did Cara Therapeutics Stock Go Up Last Month?
Cara Therapeutics share price went up by 16.72% last month -
Did CARA's Share Price Rise Over The Last Year?
CARA share price fell by -69.31% over the past 1 year
What Is Cara Therapeutics 52-Week High & Low?
-
What Is Cara Therapeutics’s 52-Week High Share Price?
Cara Therapeutics has traded as high as $1.31 over the past 52 weeks -
What Is Cara Therapeutics’s 52-Week Low Share Price?
Cara Therapeutics has traded as low as $0.24 over the past 52 weeks
Cara Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Cara Therapeutics?
-
How Much Debt Does Cara Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Cara Therapeutics Have?
Cash and short term investments quarterly total is $42M -
What Is Cara Therapeutics’s Book Value Per Share?
Book value per share is 0.01
Is Cara Therapeutics Cash Flow Positive?
-
What Is CARA Cash Flow From Operations?
Cash flow from operations (TTM) is -$74.2M -
What Is Cara Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $34.5M -
What Is Cara Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $13.5M
Cara Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
CARA return on invested capital is -258.41% -
What Is Cara Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -104.95% -
What Is CARA Return On Equity?
ROE is a measure of profitability and is -258.41%
Cara Therapeutics Earnings Date & Stock Price
-
What Is Cara Therapeutics's Stock Price Today?
A single share of CARA can be purchased today for 0.31 -
What Is Cara Therapeutics’s Stock Symbol?
Cara Therapeutics trades on the nasdaq under the ticker symbol: CARA -
When Is Cara Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Cara Therapeutics is scheduled on March 4, 2025 -
When Is CARA's next ex-dividend date?
Cara Therapeutics's next ex-dividend date is May 7, 2020 -
How To Buy Cara Therapeutics Stock?
You can buy Cara Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Cara Therapeutics Competitors
-
Who Are Cara Therapeutics's Competitors?
Below is a list of companies who compete with Cara Therapeutics or are related in some way:
Cara Therapeutics Dividend Yield
-
What Is CARA Dividend Yield?
Cara Therapeutics’s dividend yield currently is 0% -
What Is Cara Therapeutics’s Payout Ratio?
Cara Therapeutics’s payout ratio is 0% -
When Did Cara Therapeutics Last Pay A Dividend?
The latest dividend pay date is November 23, 2024 -
What Is Cara Therapeutics’s Dividend Per Share?
Cara Therapeutics pays a dividend of $0.00 per share
Cara Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 51.81% |
Revenue: | -47.47% | 58.14% |
Analyst Recommendations
Buy Recommendations: | 0 |
---|---|
Hold Recommendations: | 4 |
Sell Recommendations: | 0 |
Price Target: | 1.66 |
Upside from Last Price: | 433.87% |